Compare LTC Properties Inc (LTC) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LTC Properties Inc vs Spyre Therapeutics Inc. Common Stock — how do they compare? LTC Properties Inc trades at $43.09 (market cap $2.31B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 3.3× LTC Properties Inc's market cap, and LTC Properties Inc pays a 5.31% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold LTC Properties Inc for 89 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| LTC | SYRE | |
|---|---|---|
Market Cap | $2.31B | $7.52B |
Volume | 323,404 | 1,441,031 |
Sector | Real Estate | Health |
52-Week High | $43.50 | $108.92 |
52-Week Low | $34.04 | $22.18 |
Typical Hold Time | 89 Days | 0 Days |
Enterprise Value | $3.05B | $6.52B |
Dividend Yield | 5.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LTC Properties trades at $43.20, up 0.35% with a bullish technical signal and strong fundamental metrics including 38.93% net income margin and 12.11% ROE. Recent acquisitions totaling $360 million accelerate the SHOP portfolio transition, while consistent monthly dividends of $0.19 provide income stability. Revenue growth continues with 2025 revenue reaching $263 million, though profit margins have moderated from historical highs.
The outlook remains positive with analyst consensus target of $49.67 representing 15% upside potential. Key risks include rising interest rates impacting REIT valuations and execution challenges in portfolio transformation. The stock offers balanced risk-reward with income generation and growth potential from strategic acquisitions in the seniors housing sector.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LTC Properties Inc
LTC Properties Inc is a healthcare facility real estate investment trust. The company operates one segment that works to invest in healthcare facilities through mortgage loans, property lease transactions, and other investments. LTC generates all of its revenue in the United States. LTC is an active capital provider in the seniors housing and health care real estate industry. The company has been actively engaged with its operating partners to create a growing pipeline of projects. LTC considers merger and acquisition investment as a component of its operational growth strategy.
Read more on LTC →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
